INSPIREMD 1/18 DL-0001 Cash Flow Conversion Efficiency
INSPIREMD 1/18 DL-0001 cash flow conversion efficiency. Based on the latest financial reports, INSPIREMD 1/18 DL-0001 (II2) has a cash flow conversion efficiency ratio of -0.169x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.35 Million ≈ $-10.93 Million USD) by net assets (€55.20 Million ≈ $64.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of INSPIREMD 1/18 DL-0001 (2021–2025)
Cash flow conversion efficiency of INSPIREMD 1/18 DL-0001 from 2021 to 2025. This chart illustrates how INSPIREMD 1/18 DL-0001's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INSPIREMD 1/18 DL-0001 stock quote for real-time trading data and today's change.
INSPIREMD 1/18 DL-0001 Cash Flow Conversion Ratio Explained
INSPIREMD 1/18 DL-0001 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
INSPIREMD 1/18 DL-0001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INSPIREMD 1/18 DL-0001 ranked by their cash flow conversion efficiency. Also see market cap of INSPIREMD 1/18 DL-0001 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
0.051x |
|
Jindo.Co. Ltd
KO:088790
|
0.016x |
|
Eden Inc Bhd
KLSE:7471
|
0.026x |
|
AJ Advance Technology Public Company Limited
BK:AJA
|
-0.019x |
|
Blackrock World Mining Trust Plc
LSE:BRWM
|
0.012x |
|
Delko S.A.
WAR:DEL
|
-0.003x |
|
BCWORLD PHARM. Co. Ltd
KQ:200780
|
0.020x |
|
Parkway Corporate Ltd
AU:PWN
|
-0.011x |
Annual Cash Flow Conversion Efficiency for INSPIREMD 1/18 DL-0001 (2021–2025)
The table below shows the annual cash flow conversion efficiency of INSPIREMD 1/18 DL-0001 from 2021 to 2025. Review INSPIREMD 1/18 DL-0001 leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €55.20 Million ≈ $64.54 Million |
€-35.10 Million ≈ $-41.04 Million |
-0.636x | -4.94% |
| 2024-12-31 | €36.09 Million ≈ $42.19 Million |
€-21.87 Million ≈ $-25.57 Million |
-0.606x | -46.17% |
| 2023-12-31 | €39.50 Million ≈ $46.18 Million |
€-16.38 Million ≈ $-19.15 Million |
-0.415x | +53.61% |
| 2022-12-31 | €17.39 Million ≈ $20.33 Million |
€-15.54 Million ≈ $-18.17 Million |
-0.894x | -126.82% |
| 2021-12-31 | €33.53 Million ≈ $39.20 Million |
€-13.21 Million ≈ $-15.44 Million |
-0.394x | -- |
About INSPIREMD 1/18 DL-0001
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard c… Read more